Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
>Upward revision to revenue and EBITDA for FY 2023-24 (16 months) - 2CRSi yesterday evening issued a press release announcing an increase in its financial targets for FY 2023-24 to end-June 2024 (16 months). Whereas at the announcement of the capital increase (12 March 2024) the company had guided to FY 2023-24 revenue of € 150m with an EBITDA margin above 3%, it announced yesterday evening that it was raising its guidance for the financial year to revenue of € 190m w...
>Révision à la hausse du CA et de l’EBITDA pour l’exercice 2023-204 (16 mois) - Hier soir 2CRSi a publié un communiqué pour annoncer une révision à la hausse de ses objectifs financiers pour l’exercice 2023-2024 se terminant à fin juin 2024 (16 mois). Alors que la société guidait lors de l’annonce de l’augmentation de capital (12 mars 2024) sur un CA 2023-2024 de 150 M€ avec une marge d’EBITDA supérieure à 3%, elle relève sa guidance pour ce même exercice à 190 M€ ave...
A director at BB Biotech AG bought 1,000 shares at 41.450CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.
Azerion continues expansion in the Nordics by acquiring 26% of Eniro Amsterdam, 26 April 2024 - Azerion announces today a strategic investment in Eniro Group AB (“Eniro”) executed through the purchase of approximately 26% of its ordinary shares. This is another important step in executing Azerion’s strategy to build one of Europe’s largest digital advertising platforms, integrating networks of digital audiences, publishing and advertising technology. As part of the strategic partnership, Azerion will acquire the shares in Eniro from its two largest current shareholders, SpectrumOne AB and B...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
>Lower than expected organic growth and EBITA. Disappointing FCF - Tietoevry reported its Q1 2024 results yesterday before market opening. Organic growth was -2.0% year-on-year (vs. ODDO BHF estimate of -0.2%), which represents a slowdown relative to 1% in Q4. Growth was impacted by a poor performance in 1/ Tech Services (organic growth of -7% vs. ODDO BHF estimate of -4.8%); 2/ Create (organic growth of -5% vs. ODDO BHF estimate of -0.7%), due to the ongoing weak eco...
>Top line with positive momentum, but below expectations - Stratec’s Q1 2024 revenues of € 50.9m (-17.2% y-o-y) was impacted by a -15.7% decline at constant currencies), which were -17%/-18% below our and the consensus’ expectations. The consolidation of Natech Plastics contributed around 470bp to revenues growth. The first quarter was impacted by destocking as guided before, but the headwind was more severe than expected. Bottom line with sequential grow...
>Croissance org. et EBITA, inférieurs aux attentes. FCF décevant - TietoEVRY a publié hier avant Bourse ses résultats T1 2024. La croissance org. ressort à -2.0% y/y(vs ODDO BHF :-0.2% org), en décélération par rapport au T4 (1% org.). La croissance a été impactée par une faible performance sur les segments 1/ Tech Services (-7% org. vs ODDO BHF : -4.8% org.); 2/ Create (-5% org. vs ODDO BHF : -0.7% org.), en raison de la faiblesse persistante de l'environnement écon...
EQS-News: BB BIOTECH AG / Key word(s): Interim Report BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates 26.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at April 26, 2024 Portfolio of BB Biotech AG as at March 31, 2024 BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates Investor sentiment in the biotech space continues to be shaped by the general interest rate environment. Biot...
EQS-News: BB BIOTECH AG / Schlagwort(e): Zwischenbericht BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt von Zinserwartungen geprägt 26.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 26. April 2024 Portfolio der BB Biotech AG per 31. März 2024 BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt von Zinserwartungen geprägt Das Zinsumfeld bestimmt weiterhin massgeblich die Stimmung der Biotechinvestoren. Die Aktienkurse entwickelten sich zu Beginn des Jahres vielversprechend...
EQS-News: STRATEC SE / Key word(s): Quarter Results STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2024 26.04.2024 / 06:55 CET/CEST The issuer is solely responsible for the content of this announcement. STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2024 Subdued start to financial year as expected, but noticeable revival apparent in market and very strong sales growth expected for second quarter of 2024 Consolidated sales Q1/2024 -15.7% at constant currency to € 50.9 million (Q1/2023: € 60.5 million) Efficiency measures and structural changes taking effect: Despite negative s...
EQS-News: STRATEC SE / Schlagwort(e): Quartalsergebnis STRATEC BERICHTET ZAHLEN ZUM ERSTEN QUARTAL 2024 26.04.2024 / 06:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. STRATEC BERICHTET ZAHLEN ZUM ERSTEN QUARTAL 2024 Erwartungsgemäß verhaltener Start ins Geschäftsjahr, jedoch spürbare Marktbelebung beobachtbar und sehr starkes Umsatzwachstum im zweiten Quartal 2024 erwartet Konzernumsatz in Q1/2024 währungsbereinigt -15,7% bei 50,9 Mio. € (Q1/2023: 60,5 Mio. €) Effizienzmaßnahmen und strukturelle Änderung entfalten Wirkung: Adju...
Correction: Publication of 2023 Annual Report of Azerion Group N.V. Amsterdam, 25 April 2024 – Azerion announces that it has today published its annual report and audited financial results for the full year 2023 for Azerion Group N.V.. The Annual Report can be found at . Contact:Investor Relations Media About Azerion Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe’s largest digital advertising and entertainment media platforms. Azerion brings global scaled audiences to advertisers in an easy and cost-effective way, delivered through our proprietary technolog...
Publication of 2023 Annual Report of Azerion Group N.V. Amsterdam, 25 April 2024 – Azerion announces that it has today published its annual report and audited financial results for the full year 2023 for Azerion Group N.V.. The Annual Report can be found at . Contact:Investor Relations Media About Azerion Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe’s largest digital advertising and entertainment media platforms. Azerion brings global scaled audiences to advertisers in an easy and cost-effective way, delivered through our proprietary technology, in a safe...
BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements pour les maladies du cerveau, annonce la mise à disposition de son Document d’Enregistrement Universel 2023 approuvé par l’Autorité des marchés financiers (AMF), le 24 avril 2024 sous le numéro R.24-004. Le Document d'Enregistrement Universel 2023 inclut notamment : le rapport financier annuel 2023 ; les rapports du Commissaire aux Comptes ; les informations relati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.